Efficacy of Ketamine in Depression: A Rapid-Acting Antidepressant
May 14, 2019 DOI: 10.64239/pi-vl1404 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Population | Individuals with treatment-resistant depression |
| Intervention | Ketamine |
| Dose | a single dose |
| Topics | Depression Esketamine Ketamine |
| Key findings | Ketamine's response rate dropped from 64% to 71% in efficacy studies to about 50% in real-world clinical settings. |
Abstract
Ketamine has emerged as the prototypical rapid-acting antidepressant. Early efficacy studies showed a high rate of response (64% to 71%) to a single dose of ketamine among individuals with treatment-resistant depression. Later clinical reports of the effectiveness of ketamine in clinical samples demonstrated a response rate of approximately 50%. This discrepancy between efficacy and effectiveness is frequently seen as new treatments are taken from clinical trials to real-world settings.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |